2020 top stories in kidney cancer

This article summarises the key breakthroughs in the treatment of renal cell carcinoma (RCC) in 2020, including a new first-line VEGF-TKI and immunotherapy combination (cabozantinib plus nivolumab) and immunotherapy as a new standard of treatment for patients with non−clear cell RCC and sarcomatoid RCC.

Read more in Practice Update here

Watch a video interview on Urology Today with Dr Ramaprasad Srinivasan from the National Cancer Institute in the USA, where he summarises the latest advances in treatment for kidney cancer, including the HIF 2alpha inhibitor (MK6482) for the treatment of VHL-associated kidney cancer.

Share this Post!


Related post

  TOP